QUBIS β 2022 Investments
4 investments dated 2022 Β· listed companies and verified rows first Β· show all
Aramune develops pharmaceutical and nutraceutical products targeting diseases including diabetes, obesity, cardiovascular disease, and neurodegenerative conditions.
AgTechBiotechFoodTechHealthtechMedical DevicesBelfast, GB
Brian(Professor of Molecular Nutrition)Chris Nicklin
BoardStuart
Co-investorsClarendon Fund Managers Ltd.
Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.
AI & Machine LearningData & Infrastructure
Art Abal(Founder)
Co-investorsAbstract VenturesAlphaLab CapitalCaladanEarl Grey CapitalParadigmSCB 10X+7 more
Vana provides open data infrastructure for AI that lets individuals control the data they create and choose how it is used.
AI & Machine LearningCrypto & Web3Data & Infrastructure
Co-investorsFlori VenturesBoxGroupCoinbase VenturesDeFiance CapitalExSight VenturesGSR+7 more
VascVersa develops a platform for vascular stem cell therapy and cell therapy manufacturing, serving the advanced therapies and clinical development sectors in vascular biology.
BiotechDeep TechHealthtechBelfast, GB
Professor Alan Stitt(Co-founder)Dr Christina O'Neill(Co-founder, CEO)Prof Reinhold Medina(Co-founder)
Co-investorsClarendon Fund Managers Ltd.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.